NO900155L - Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. - Google Patents

Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Info

Publication number
NO900155L
NO900155L NO90900155A NO900155A NO900155L NO 900155 L NO900155 L NO 900155L NO 90900155 A NO90900155 A NO 90900155A NO 900155 A NO900155 A NO 900155A NO 900155 L NO900155 L NO 900155L
Authority
NO
Norway
Prior art keywords
sicam
icam
purified
different
relates
Prior art date
Application number
NO90900155A
Other languages
English (en)
Other versions
NO900155D0 (no
Inventor
Jeffrey Greve
Alan Mcclelland
Original Assignee
Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26972210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO900155(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/301,192 external-priority patent/US5235049A/en
Application filed by Molecular Therapeutics Inc filed Critical Molecular Therapeutics Inc
Publication of NO900155D0 publication Critical patent/NO900155D0/no
Publication of NO900155L publication Critical patent/NO900155L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70525ICAM molecules, e.g. CD50, CD54, CD102
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bipolar Transistors (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En oppløselig form av Intercellulært adhesjonsmolekyl (sICAW-1) og renset og isolert humant sICAW-1, er beskrevet. En renset og Isolert DNA-sekvens kodende for sICAM-l er også beskrevet. Den ekstracellulære domenen til sICAW-l og uoppløselig ICAM-1 er vesentlig Ilke. ICAW-1 er Involvert 1 prosessen hvor Isrmfocytter kobles til cellulære substrater 1 løpet av betennelse og virker som hovedhuæan-rhlnovlrusreseptor (HRR). sICAW-1 både reduserer Imraunbetennelse og temmer Infeksjon av rhlnovlrus og Coxsackle A-vlrus.
NO90900155A 1989-01-24 1990-01-11 Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. NO900155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,192 US5235049A (en) 1989-01-24 1989-01-24 Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US44595189A 1989-12-13 1989-12-13

Publications (2)

Publication Number Publication Date
NO900155D0 NO900155D0 (no) 1990-01-11
NO900155L true NO900155L (no) 1990-07-25

Family

ID=26972210

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90900155A NO900155L (no) 1989-01-24 1990-01-11 Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Country Status (15)

Country Link
EP (1) EP0379904B1 (no)
JP (1) JP3080631B2 (no)
KR (1) KR100202435B1 (no)
AT (1) ATE137799T1 (no)
AU (1) AU641134B2 (no)
DE (1) DE69026844T2 (no)
DK (1) DK0379904T3 (no)
ES (1) ES2087091T3 (no)
FI (1) FI100601B (no)
GR (1) GR3020481T3 (no)
IE (1) IE74144B1 (no)
IL (1) IL93119A (no)
NO (1) NO900155L (no)
NZ (1) NZ232203A (no)
PT (1) PT92920B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
HU217792B (hu) * 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0391088B1 (en) * 1989-03-16 1997-01-02 Center For Blood Research, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
AU710965B2 (en) * 1992-06-22 1999-09-30 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
FR2710778B1 (fr) * 1993-09-29 1995-12-01 Framatome Sa Grappe de commande pour réacteur nucléaire et réacteur en faisant application.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
ES2201547T3 (es) * 1997-10-02 2004-03-16 Icos Corporation Icam-4 y usos diagnosticos de las mismas.
FR2788161B1 (fr) * 1998-12-30 2001-03-23 Framatome Sa Crayon absorbant pour grappe de commande de reacteur nucleaire
IL145480A0 (en) 1999-03-19 2002-06-30 Genentech Inc Treatment of lfa-1 associated disorders with increasing doses of lfa-1
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
WO2004074815A2 (en) * 2003-02-14 2004-09-02 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
JP4671323B2 (ja) * 2004-04-28 2011-04-13 大日本印刷株式会社 ディスプレイ装置
WO2005123777A2 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128727T1 (de) * 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
AU636230B2 (en) * 1990-10-24 1993-04-22 Dolores Y. Beaupied Garment to hold an ostomy appliance

Also Published As

Publication number Publication date
FI100601B (fi) 1998-01-15
KR100202435B1 (ko) 1999-06-15
JP3080631B2 (ja) 2000-08-28
PT92920B (pt) 1995-12-29
DK0379904T3 (da) 1996-09-16
EP0379904B1 (en) 1996-05-08
IL93119A (en) 1999-07-14
NO900155D0 (no) 1990-01-11
IE74144B1 (en) 1997-07-02
JPH0381296A (ja) 1991-04-05
NZ232203A (en) 1992-10-28
PT92920A (pt) 1990-07-31
IL93119A0 (en) 1990-11-05
AU4876790A (en) 1990-08-02
DE69026844D1 (de) 1996-06-13
FI900331A0 (fi) 1990-01-22
KR900011895A (ko) 1990-08-02
ES2087091T3 (es) 1996-07-16
IE900257L (en) 1990-07-24
ATE137799T1 (de) 1996-05-15
EP0379904A1 (en) 1990-08-01
GR3020481T3 (en) 1996-10-31
AU641134B2 (en) 1993-09-16
DE69026844T2 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
NO900155D0 (no) Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368A1 (en) Soluble molecule related to but distinct from icam-1
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
ATE289519T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
NZ520071A (en) 4-aminopiperidine derivatives and their use as medicine
IL142499A0 (en) Building units for synthesis of backbone cyclized peptide analogs
ES2121915T3 (es) Ligandos del receptor eck.
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
TR200000015T2 (tr) Bileşikler ve metodlar
GR3023797T3 (en) Mitogen-free substance, its preparation and its use.
MX9702932A (es) L-ribofuranosilnucleosidos.
DE68923048D1 (de) Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
FI892454A7 (fi) Uudet bentsimidatsolijohdannaiset, menetelmät niiden valmistamiseksi j a niitä sisältävä farmaseuttinen seos
KR900002799A (ko) 뉴로펩티드 y 애고니스트
DE69804839D1 (de) Cd8 als inhibitor des zellulären immunsystems
GR1000719B (el) Μεθοδος παρασκευης της (s)-α-εθυλ-2-οξο-1-πυρρολιδινοακεταμιδης.
DK0526649T3 (da) Carboxymethylmannoglucan og derivater deraf.
HUP0003174A2 (hu) 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
ES8608884A1 (es) Un procedimiento de eliminacion del virus lav.
ATE83242T1 (de) Cysteinreiche, gamma-glutaminsaeure und betaalanin-einheitenaufweisende peptide, verfahren zu deren herstellung und ihre verwendung.
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
KATZ et al. Synthesis, characterization and inhibitory activities of (4‐N3 [3, 5‐3H] Phe10) PKI (6–22) amide and its precursors: photoaffinity labeling peptides for the active site of cyclic AMP‐dependent protein kinase
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları